Farallon Capital Management LLC Increases Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Farallon Capital Management LLC raised its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 1.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,654,502 shares of the biopharmaceutical company's stock after purchasing an additional 63,900 shares during the quarter. Agios Pharmaceuticals accounts for approximately 1.2% of Farallon Capital Management LLC's investment portfolio, making the stock its 25th largest holding. Farallon Capital Management LLC owned approximately 9.96% of Agios Pharmaceuticals worth $243,822,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in AGIO. Acadian Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals during the second quarter valued at $37,000. Quest Partners LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at about $40,000. NEOS Investment Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $210,000. North Star Asset Management Inc. bought a new position in shares of Agios Pharmaceuticals during the second quarter valued at approximately $216,000. Finally, XTX Topco Ltd bought a new stake in Agios Pharmaceuticals during the 2nd quarter valued at $230,000.

Insiders Place Their Bets

In other news, CEO Brian Goff sold 11,091 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.93% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently commented on AGIO shares. Royal Bank of Canada reissued an "outperform" rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. StockNews.com lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, August 5th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Friday. Finally, The Goldman Sachs Group boosted their target price on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a "neutral" rating in a research note on Tuesday, June 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $51.33.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock traded up $0.83 during mid-day trading on Tuesday, reaching $46.59. 339,384 shares of the company traded hands, compared to its average volume of 705,557. Agios Pharmaceuticals, Inc. has a fifty-two week low of $19.80 and a fifty-two week high of $50.35. The firm's fifty day moving average is $45.68 and its two-hundred day moving average is $39.34. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of -7.38 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The firm had revenue of $8.60 million during the quarter, compared to analysts' expectations of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The company's revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.51) earnings per share. As a group, equities research analysts predict that Agios Pharmaceuticals, Inc. will post -4.85 earnings per share for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.